Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Université Paul Sabatier, , Toulouse Cedex 3, France.
Blood. 2011 Jun 16;117(24):6627-37. doi: 10.1182/blood-2010-09-301994. Epub 2011 Apr 6.
Although deregulated expression of specific microRNAs (miRNAs) has been described in solid cancers and leukemias, little evidence of miRNA deregulation has been reported in ALK-positive (ALK(+)) anaplastic large cell lymphomas (ALCL). These tumors overexpress the major antiapoptotic protein myeloid cell leukemia 1 (MCL-1), a situation that could compensate for the lack of BCL-2. We report that ALK(+) ALCL cell lines and biopsy specimens (n = 20) express a low level of miR-29a and that this down-modulation requires an active NPM-ALK kinase. Murine models (transgenic mice and mouse embryonic fibroblast [MEF] cells), which allow conditional NPM-ALK fusion protein expression, showed an increase of miR-29a expression in the absence of NPM-ALK. Concordant results were observed after the abolition of NPM-ALK kinase activity (siALK or PF-2341066) in NPM-ALK(+) ALCL cell lines. In addition, we showed that low expression of miR-29a, probably through methylation repression, plays an important regulatory role in MCL-1 overexpression that could promote tumor cell survival by inhibiting apoptosis. Enforced miR-29a expression was found to modulate apoptosis through inhibition of MCL-1 expression in ALCL cell lines and in a xenografted model, with a concomitant tumor growth reduction. Thus, synthetic miR-29a represents a potential new tool to affect tumorigenesis in these lymphomas.
虽然特定 microRNAs(miRNAs)的失调表达已在实体瘤和白血病中被描述,但在 ALK 阳性(ALK(+))间变性大细胞淋巴瘤(ALCL)中,miRNA 失调的证据很少。这些肿瘤过度表达主要的抗凋亡蛋白髓样细胞白血病 1(MCL-1),这种情况可以弥补 BCL-2 的缺乏。我们报告说,ALK(+) ALCL 细胞系和活检标本(n=20)表达低水平的 miR-29a,这种下调需要有活性的 NPM-ALK 激酶。允许条件性 NPM-ALK 融合蛋白表达的小鼠模型(转基因小鼠和小鼠胚胎成纤维细胞[MEF]细胞)在没有 NPM-ALK 的情况下显示 miR-29a 表达增加。在 NPM-ALK(+) ALCL 细胞系中消除 NPM-ALK 激酶活性(siALK 或 PF-2341066)后观察到了一致的结果。此外,我们表明,miR-29a 的低表达,可能通过甲基化抑制,在 MCL-1 过表达中发挥重要的调节作用,通过抑制细胞凋亡促进肿瘤细胞存活。在 ALCL 细胞系和异种移植模型中,强制表达 miR-29a 通过抑制 MCL-1 表达被发现可调节细胞凋亡,同时伴随肿瘤生长减少。因此,合成 miR-29a 可能代表了一种影响这些淋巴瘤发生的新工具。